This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Community Health (CYH) Stock
by Zacks Equity Research
With contract labor headwinds likely to phase out as 2022 progresses, Community Health Systems' (CYH) margins are set to improve significantly.
Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View
by Zacks Equity Research
Anthem's (ANTM) Medicaid footprint is likely to grow on the back of the pending acquisition of Paramount Advantage's Ohio contracts, as service is expected to commence in July.
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 24.2% in 4 Weeks, Here's Why the Trend Might Reverse for Neuronetics (STIM)
by Zacks Equity Research
Neuronetics (STIM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
New Strong Sell Stocks for August 25th
by Zacks Equity Research
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
New Strong Sell Stocks for August 6th
by Zacks Equity Research
AVA, IDN, KOPN, PRIM, and STIM have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2021.
Neuronetics (STIM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -20.83% and -3.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 6.06% and 6.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 24.00% and 2.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Soars 6.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neuronetics (STIM) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 41.94% and 11.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.